{"id":"NCT00626782","sponsor":"Wills Eye","briefTitle":"Lucentis Versus Mitomycin C During Glaucoma Surgery","officialTitle":"Lucentis Versus Mitomycin C as Adjunctive Agent During Trabeculectomy Surgery","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2008-01","primaryCompletion":"2011-04","completion":"2011-04","firstPosted":"2008-02-29","resultsPosted":"2015-03-13","lastUpdate":"2018-03-22"},"enrollment":24,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Glaucoma"],"interventions":[{"type":"DRUG","name":"Ranibizumab","otherNames":["Lucentis"]},{"type":"DRUG","name":"Mitomycin (MMC)","otherNames":["MMC C 0.4 mg/ml"]}],"arms":[{"label":"A: Ranibizumab 0.5mg (0.05mL) injection","type":"EXPERIMENTAL"},{"label":"B: Mitomycin C 0.4 mg/ml sponge","type":"ACTIVE_COMPARATOR"}],"summary":"Does a new add on (or adjunctive) therapy used in glaucoma surgery improve the success of trabeculectomy? Ranibizumab may offer benefit similar to mitomycin C in preventing epi-scleral fibrosis while avoiding the well known complications of mytomycin C which include late bleb leaks, hypotony and infection.","primaryOutcome":{"measure":"Adverse Events","timeFrame":"12 months","effectByArm":[{"arm":"Treatment 1 (Ranibizumab 0.5mg)","deltaMin":100,"sd":null},{"arm":"Treatment 2 (Mitomycin C 0.4 mg/ml)","deltaMin":16.67,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":5},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["25019269"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":12},"commonTop":["needling of the bleb","choroidal detachment","optic nerve swelling","choroidal folds","macular/retinal folds"]}}